Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to
be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial …

Фибрилляция предсердий (ФП) увеличивает риск развития инсульта, поэтому
долгосрочная антикоагулянтная терапия является стандартом лечения абсолютного …

Background Death of patients presenting with bleeding events to the Emergency
Department still represent a major problem. We sought to analyze clinical characteristics …

Hintergrund und Methoden: Patienten mit nicht valvulärem Vorhofflimmern (nv VHF) haben
ein erhöhtes Risiko für die Entstehung linksatrialer Thromben und damit für das Auftreten …

Despite direct oral anticoagulants (DOACs) have overcome the most relevant limitations of
vitamin K antagonists, many patients with atrial fibrillation are not receiving the appropriate …

Despite evidence of significant clinical benefit, for patients with cardiovascular disease,
adherence and persistence to treatment is often problematic. Once Daily dosing may …

Thromboembolic complications are the most important outcomes of atrial fibrillation (AF).
New oral anticoagulants (NOACs) have been presented to protect non-valvular AF patients …

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is
responsible for 20-30% of all strokes. AF-related strokes are more severe, and result in …

Novel oral anticoagulants (NOACs) have uncomplicated dosing with no need for INR
monitoring and fewer possible drug and food interactions compared to warfarin, which may …

Oral anticoagulants such as vitamin-K antagonists (VKA) are prescribed for the prevention
and management of venous thromboembolism, and for the prevention of ischemic stroke in …